MDT vs. BSX, CI, VRTX, REGN, ELV, BMY, SNY, GSK, SYK, and HCA
Should you be buying Medtronic stock or one of its competitors? The main competitors of Medtronic include Boston Scientific (BSX), The Cigna Group (CI), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Elevance Health (ELV), Bristol-Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), Stryker (SYK), and HCA Healthcare (HCA). These companies are all part of the "medical" sector.
Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation, dividends and community ranking.
89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 82.1% of Medtronic shares are owned by institutional investors. 0.5% of Boston Scientific shares are owned by insiders. Comparatively, 0.3% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Medtronic has a net margin of 13.00% compared to Medtronic's net margin of 12.06%. Medtronic's return on equity of 16.63% beat Boston Scientific's return on equity.
Medtronic received 582 more outperform votes than Boston Scientific when rated by MarketBeat users. Likewise, 76.53% of users gave Medtronic an outperform vote while only 69.31% of users gave Boston Scientific an outperform vote.
Medtronic has higher revenue and earnings than Boston Scientific. Medtronic is trading at a lower price-to-earnings ratio than Boston Scientific, indicating that it is currently the more affordable of the two stocks.
In the previous week, Boston Scientific had 28 more articles in the media than Medtronic. MarketBeat recorded 47 mentions for Boston Scientific and 19 mentions for Medtronic. Boston Scientific's average media sentiment score of 0.68 beat Medtronic's score of 0.13 indicating that Medtronic is being referred to more favorably in the news media.
Boston Scientific currently has a consensus target price of $75.09, indicating a potential upside of 3.53%. Medtronic has a consensus target price of $94.91, indicating a potential upside of 16.27%. Given Boston Scientific's higher probable upside, analysts plainly believe Medtronic is more favorable than Boston Scientific.
Boston Scientific has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
Summary
Boston Scientific beats Medtronic on 10 of the 19 factors compared between the two stocks.
Get Medtronic News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medtronic Competitors List
Related Companies and Tools
